



RSM Danmark

Statsautoriseret
Revisionspartnerselskab

Ved Vesterport 6, 5. sal
1612 København
T +45 33 93 22 33

CVR nr. 25 49 21 45

kobenhavn@rsm.dk
www.rsm.dk

The Medicines Company Dk ApS

c/o BRANDT revision, Ved Vesterport 6, 5., 1612 København V

Company reg. no. 40 25 93 17

Annual report

1 January - 31 December 2020

The annual report was submitted and approved by the general meeting on the 30 June 2021.

Carsten Gleerup
Chairman of the meeting

Notes:

- To ensure the greatest possible applicability of this document, IAS/IFRS English terminology has been used.
- Please note that decimal points have not been used in the usual English way. This means that for instance DKK 146.940 means the amount of DKK 146,940, and that 23,5 % means 23.5 %.

Contents

	<u>Page</u>
Reports	
Management's report	1
Auditor's report on compilation of the financial statements	2
Company information	
Company information	3
Financial statements 1 January - 31 December 2020	
Income statement	4
Statement of financial position	5
Notes	6

Management's report

Today, the executive board has presented the annual report of The Medicines Company Dk ApS for the financial year 1 January - 31 December 2020.

The annual report has been presented in accordance with the Danish Financial Statements Act.

We consider the accounting policies appropriate and, in our opinion, the financial statements provide a fair presentation of the company's assets, equity and liabilities, and financial position at 31 December 2020 and of the company's results of activities in the financial year 1 January – 31 December 2020.

The executive board consider the conditions for audit exemption of the 2020 financial statements to be met.

We recommend that the annual report be approved by the general meeting.

Copenhagen, 30 June 2021

Executive board

Carsten Gleerup

Peter Drøidal

Auditor's report on compilation of the financial statements

To the shareholders of The Medicines Company Dk ApS

We have compiled the financial statements of The Medicines Company Dk ApS for the financial year 1 January - 31 December 2020 based on the company's bookkeeping and on further information provided by you.

The financial statements comprise the income statement, statement of financial position, notes.

We performed this engagement in accordance with the international standard ISRS 4410 applying to compilation engagements.

We have applied our professional expertise to assist you in the preparation and presentation of the financial statements in accordance with the Danish Financial Statements Act. We have complied with relevant requirements of the Danish Act on Approved Auditors and Audit Firms and with ethical requirements of the Danish Institute of State Authorised Public Accountants, including principles of integrity, objectivity, professional competence and due care.

The financial statements and the accuracy and completeness of the information used to compile them are your responsibility.

As a compilation engagement is not an assurance engagement, we are not required to verify the accuracy or completeness of the information you provided to us in order to compile the financial statements. Accordingly, we express neither an audit opinion nor a review opinion as to whether the financial statements have been compiled in accordance with the Danish Financial Statements Act.

Copenhagen V, 30 June 2021

RSM Danmark

Statsautoriseret Revisionspartnerselskab
Company reg. no. 25 49 21 45

Martin Enderberg Lassen
State Authorised Public Accountant
mne40044

Company information

The company

The Medicines Company Dk ApS
c/o BRANDT revision
Ved Vesterport 6, 5.
1612 København V

Company reg. no. 40 25 93 17

Financial year: 1 January 2020 - 31 December 2020

Executive board

Carsten Gleerup
Peter Drøidal

Auditors

RSM Danmark Statsautoriseret Revisionspartnerselskab
Ved Vesterport 6, 5. sal
1612 København V

Income statement

All amounts in DKK.

<u>Note</u>	<u>1/1 - 31/12 2020</u>	<u>11/2 - 31/12 2019</u>
Gross loss	-76.180	-41.218
Operating profit	-76.180	-41.218
Pre-tax net profit or loss	-76.180	-41.218
Profit or loss from ordinary activities after tax	-76.180	-41.218
Net profit or loss for the year	<u>-76.180</u>	<u>-41.218</u>
Proposed appropriation of net profit:		
Allocated from retained earnings	<u>-76.180</u>	<u>-41.218</u>
Total allocations and transfers	<u>-76.180</u>	<u>-41.218</u>

Statement of financial position at 31 December

All amounts in DKK.

<u>Note</u>	<u>2020</u>	<u>2019</u>
Assets		
Current assets		
Other receivables	97.160	31.595
Total receivables	97.160	31.595
Total current assets	97.160	31.595
Total assets	97.160	31.595
Equity and liabilities		
Equity		
Contributed capital	50.000	50.000
Retained earnings	-25.690	-41.218
Total equity	24.310	8.782
Liabilities other than provisions		
Trade payables	72.850	22.813
Total short term liabilities other than provisions	72.850	22.813
Total liabilities other than provisions	72.850	22.813
Total equity and liabilities	97.160	31.595

- 1 The significant activities of the enterprise
- 2 Micro enterprise

Notes

All amounts in DKK.

1/1 - 31/12 2020	11/2 - 31/12 2019
---------------------	----------------------

1. The significant activities of the enterprise

The objective of the Company is to develop and commercialize pharmaceuticals, biotechnology and medical technology and related business. There has been no activity in 2020.

2. Micro enterprise

The annual accounts are prepared in accordance with the rules for micro enterprises identified as accounting class B enterprises. In accordance with section 22 b of the Danish Financial Statements Act, we do not state information about the following issues:

- The accounting policies used
- Debt falling due after more than 5 years
- Reversal of writedown of current assets
- Writedown of current assets exceeding usual writedown
- Average number of full-time employees during the financial year